Synairgen (LON:SNG) Shares Down 2.4% – Here’s Why

Posted by Matthew Steigler on Jan 14th, 2025

Synairgen plc (LON:SNG – Get Free Report) shares dropped 2.4% during trading on Tuesday . The stock traded as low as GBX 2.05 ($0.03) and last traded at GBX 2.19 ($0.03). Approximately 1,204,007 shares were traded during trading, a decline of 10% from the average daily volume of 1,343,892 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Trading Down 13.1 %

The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average is GBX 3.73 and its two-hundred day moving average is GBX 4. The firm has a market cap of £3.93 million, a price-to-earnings ratio of -65.00 and a beta of -2.23.

Synairgen Company Profile

(Get Free Report)

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).